Results of an observational study suggest that pregnant women with rheumatoid arthritis or axial spondyloarthritis have an elevated risk for pregnancy complications, and disease activity may be a risk factor for preterm delivery.
Phase III trial findings suggest that treatment with the phosphodiesterase 4 inhibitor apremilast is beneficial for patients with psoriatic arthritis who have not received prior treatment with conventional or biologic DMARDs.
Among patients with early rheumatoid arthritis, those who are obese are at increased risk for having worse disease activity, function, and health-related quality of life, according to an analysis of data from two UK cohorts.
The phase III CHABLIS-SC1 trial comparing blisibimod with placebo in patients with systemic lupus erythematosus has not reached its primary endpoint of improvement in the SLE responder index at 1 year, researchers report.
Researchers report that some antirheumatic drugs may limit the humoral response of patients with rheumatoid arthritis to pneumococcal vaccination, but they nonetheless stress that this should not preclude immunization against such preventable diseases.